Analyst Price Targets — INAB
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| October 13, 2025 11:46 am | — | Mizuho Securities | $4.00 | $2.11 | TheFly | IN8bio price target adjusted to $4 from $60 at Mizuho |
Latest News for INAB
IN8bio Announces Publication in The Journal of Clinical Oncology Demonstrating DeltEx™ DRI Doubles Progression-Free Survival in Newly Diagnosed Glioblastoma
First peer-reviewed publication of chemotherapy-resistant gamma-delta T cells (DeltEx Drug Resistant Immunotherapy or DRI) clinical results in newly diagnosed glioblastoma Repeat-dose patients achieved median progression-free survival (mPFS) of 16.1 months, more than double the ~6.9-month standard of care benchmark, with no dose-limiting toxicities (DLTs) NEW YORK, July 09, 2026 (GLOBE NEWSWIRE) -- IN8bio, Inc.…
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for INAB.
U.S. House Trading
No House trades found for INAB.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.